Amerigen Launches Generic Bexarotene Capsules
Amerigen Pharmaceuticals Limited ("Amerigen") today announced the commercial launch of its generic bexarotene 75mg capsules following the recent approval of the Company's corresponding Abbreviated New Drug Application ("ANDA") by the U.S. Food and Drug Administration (FDA). Amerigen's bexarotene product is a generic equivalent to Valeant Pharmaceuticals' Targretin® Capsules. Amerigen's generic bexarotene capsules are marketed by Amerigen's U.S. affiliate, Amerigen Pharmaceuticals, Inc.
The group has products on the market currently in both the U.S. and China plus an active portfolio of products under development, filed, or intended for filing, as ANDA's with the U.S. FDA and the Chinese CFDA. Amerigen's focus is orally delivered products that are challenging to develop, require specialized technologies or high containment to manufacture, and present complex regulatory and intellectual property obstacles to bring to market. All Amerigen's products are developed and manufactured by the company or its partners around the world to meet the highest quality standards, including the U.S. FDA.
SOURCE Amerigen Pharmaceuticals